Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Change in Acquisitions & Divestments (2016 - 2025)

ImmunityBio (IBRX) has disclosed Change in Acquisitions & Divestments for 11 consecutive years, with $25.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Acquisitions & Divestments rose 41.83% to $25.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $30.9 million, a 73.24% decrease, with the full-year FY2025 number at $30.9 million, down 73.24% from a year prior.
  • Change in Acquisitions & Divestments was $25.6 million for Q4 2025 at ImmunityBio, up from $5.4 million in the prior quarter.
  • In the past five years, Change in Acquisitions & Divestments ranged from a high of $49.5 million in Q3 2024 to a low of -$31.0 million in Q4 2021.
  • A 5-year average of $9.7 million and a median of $3.2 million in 2024 define the central range for Change in Acquisitions & Divestments.
  • Peak YoY movement for Change in Acquisitions & Divestments: tumbled 375.03% in 2021, then soared 48459.8% in 2024.
  • ImmunityBio's Change in Acquisitions & Divestments stood at -$31.0 million in 2021, then skyrocketed by 100.18% to $56000.0 in 2022, then skyrocketed by 382.14% to $270000.0 in 2023, then soared by 6579.26% to $18.0 million in 2024, then surged by 41.83% to $25.6 million in 2025.
  • Per Business Quant, the three most recent readings for IBRX's Change in Acquisitions & Divestments are $25.6 million (Q4 2025), $5.4 million (Q3 2025), and -$5.4 million (Q2 2025).